China Digest: Nutshell Therapeutics; Kolmostar in funding news

Source: Jan Antonin Kolar/Unsplash

Nutshell Therapeutics has garnered $20 million in a Series A round of funding led by Matrix Partners China. In a separate development, Kolmostar has secured about 100 million yuan ($16 million) in a Series A+ round led by CTC Capital.

Matrix Partners China leads funding in Nutshell Therapeutics

Shanghai-headquartered small molecule drugmaker Nutshell Therapeutics has completed raising $20 million in a Series A round led by Matrix Partners China, according to a statement on Tuesday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter